Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.57
Nov 20 • 3:59 PM ET Dollar change-0.04 Percentage change(-2.48%)
Aftermarket Close
1.57
Aftermarket • 7:51 PM ET Dollar change+0.00 Percentage change(0.01%)
Index
RUT
Market Cap
1.17B
Enterprise Value
1.29B
Income
-148.06M
Sales
501.64M
Book/sh
1.57
Cash/sh
0.53
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
2275
IPO
Nov 02, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
2.32
P/B
1.00
P/C
2.99
P/FCF
-
EV/EBITDA
-
EV/Sales
2.57
Quick Ratio
4.65
Current Ratio
4.97
Debt/Eq
0.46
LT Debt/Eq
0.44
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.27
EPS next Q
-0.06
EPS this Y
28.99%
EPS next Y
-28.35%
EPS next 5Y
2.23%
EPS past 3/5Y
13.03% -
Sales past 3/5Y
-15.45% -15.82%
EPS Y/Y TTM
18.50%
Sales Y/Y TTM
-21.87%
EPS Q/Q
-358.84%
Sales Q/Q
-56.87%
Insider Own
48.59%
Insider Trans
-0.00%
Inst Own
28.86%
Inst Trans
1.33%
ROA
-6.71%
ROE
-10.74%
ROIC
-9.20%
Gross Margin
31.58%
Oper. Margin
-29.06%
Profit Margin
-29.51%
SMA20
-6.16%
SMA50
-2.35%
SMA200
14.31%
Trades
Shs Outstand
711.66M
Shs Float
381.75M
52W High
1.86 -15.59%
52W Low
0.98 60.71%
Volatility
5.41% 4.77%
ATR (14)
0.09
RSI (14)
42.62
Beta
1.49
Rel Volume
0.93
Avg Volume
3.79M
Volume
3,517,963
Perf Week
-6.55%
Perf Month
-3.68%
Perf Quarter
6.08%
Perf Half Y
23.62%
Perf YTD
24.60%
Perf Year
20.77%
Perf 3Y
6.08%
Perf 5Y
-63.91%
Perf 10Y
-85.02%
Prev Close
1.61
Price
1.57
Change %
-2.48%
Consensus
Strong Buy
Avg. Price Target
$4.15
Implied Upside
+164.3%
Analysts8incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 16, 2026Upgrade
BBarrington Research
Mkt Perform → Outperform$2.25+43.3%
Apr 29, 2026Downgrade
BBarrington Research
Outperform → Mkt Perform
Nov 20, 2025Initiated
JPM logoJJP Morgan
Neutral
Oct 31, 2025Downgrade
JEF logoJJefferies
Buy → Hold$1.60+1.9%
Apr 25, 2025Initiated
JPM logoJJP Morgan
Neutral
Jun 29, 2023Upgrade
BBarrington Research
Mkt Perform → Outperform$2+27.4%
Dec 15, 2022Initiated
HH.C. Wainwright
Buy$3+91.1%
Jan 24, 2022Downgrade
BBarrington Research
Outperform → Mkt Perform
Jun 21, 2021Initiated
LLadenburg Thalmann
Buy$7+345.9%
Nov 25, 2019Initiated
PPiper Jaffray
Overweight$2.50+59.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAGANELLI JOHN ADirectorNov 05 '26Sale1.829,17516,6980Nov 05 04:07 PM
PAGANELLI JOHN ADirectorNov 05 '26Sale1.784,4267,878389,914Nov 05 04:07 PM
PAGANELLI JOHN ADirectorMar 20 '26Buy1.1410,00011,350394,340Mar 20 04:25 PM
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment manages the clinical laboratory operations of BioReference. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and their global pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Ph.D.Dr. Phillip Frost M.D.
Ph.D.Dr. Jane H. Hsiao M.B.A.
President & Vice Chairman of the BoardDr. Elias Adam Zerhouni M.D.
Senior VPMr. Adam E. Logal
J.D.Mr. Steven D. Rubin Esq.